New Personalized Medicine Increases Survival in Melanoma Patients

Metastatic melanoma is the deadliest and most aggressive from of skin cancer.  A person with metastatic melanoma typically has a short life expectancy that is measured in months.  

The mainstay treatments for metastatic melanoma are dacarbazine (DTIC), interleukin-2 (IL-2) and interferon (IFN).  However, efficacies of these agents are not very good. 

Less than one in four people are expected to be alive one year after diagnosis and every year there are an estimated 40,000 people worldwide die from this disease.